Top Markets
#1 Nesa Nesa +816.36%
#2 Cortex Cortex +69.03%
#3 Kinesis Silver Kinesis Silver +57.40%
#4 Merlin's Seal BTC Merlin's Seal BTC +45.76%
#5 QuantixAI QuantixAI +24.05%
#6 EXOD EXOD +22.78%
#7 OpenEden OpenEden +19.32%
#8 Palladium Network Palladium Network +18.94%
#9 Cash Cat Cash Cat +18.07%
#10 Instadapp Instadapp +16.15%
Coin of the day
Nesa Nesa
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Prometheus Biosciences, Inc. Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc.

RXDX
Classificação em ações #3433
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused... Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for its potential in addressing ulcerative colitis and Crohn's disease, both forms of IBD, as well as systemic sclerosis-associated interstitial lung disease. Beyond its lead asset, Prometheus maintains an active development pipeline featuring several other programs targeting IBD and other immune-mediated conditions: PR600: An anti-tumor necrosis factor monoclonal antibody (mAb) for IBD. PR300: A small molecule G-protein coupled receptor modulator specifically for IBD. PR1100: An anti-cytokine receptor mAb with applications in IBD and various other immune disorders. PR1800: An anti-chemokine mAb focused on IBD. PR2100: An anti-inflammatory cytokine mAb also aimed at IBD. Furthermore, the company has forged key alliances, including a diagnostic development and collaboration pact with Takeda Pharmaceutical Company Limited, a co-development and manufacturing arrangement with Dr. Falk Pharma GmbH, a licensing agreement with Cedars-Sinai Medical Center, and a strategic partnership with Millennium Pharmaceuticals, Inc. Tracing its origins, the company was initially incorporated in 2016 as Precision IBD, Inc., before rebranding to Prometheus Biosciences, Inc. in October 2019. Its corporate headquarters are situated in San Diego, California.
Preço da ação
$199.92
Última sincronização: 2023-06-15
Valor de mercado
$5.39B
Variação (1 dia)
0.09%
Variação (1 ano)
0.00%
País
US
Negociar Prometheus Biosciences, Inc. (RXDX)

Categoria

Healthcare
Histórico de preços das ações de Prometheus Biosciences, Inc. (RXDX)
Preço de fecho mais alto: $199.05 em 2023-06-01

Preço de fecho mais baixo: $20.65 em 2021-03-01
Histórico de preços das ações da Prometheus Biosciences, Inc. de 2021 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2023 108.72%
2022 183.53%
2021 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 44.02%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 541.49%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.62 -12.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $767.33 6.65%
CH